Candel Therapeutics announces oral presentation of positive Phase 3 CAN-2409 data in prostate cancer at ASCO 2025

Candel Therapeutics, Inc.

Phase 3 CAN-2409 data in localized prostate cancer accepted for oral presentation at ASCO 2025 (May 30-June 3, Chicago).
Presenter is Theodore DeWeese, M.D., Dean and CEO of Johns Hopkins Medicine.
Full abstracts released by ASCO on May 22, 2025 at 5:00 PM ET.
Candel will post presentation details on its website after the event.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.